The application of histone deacetylases inhibitors in glioblastoma.

Journal of Experimental & Clinical Cancer Research : CR
Rui ChenYali Wang

Abstract

The epigenetic abnormality is generally accepted as the key to cancer initiation. Epigenetics that ensure the somatic inheritance of differentiated state is defined as a crucial factor influencing malignant phenotype without altering genotype. Histone modification is one such alteration playing an essential role in tumor formation, progression, and resistance to treatment. Notably, changes in histone acetylation have been strongly linked to gene expression, cell cycle, and carcinogenesis. The balance of two types of enzyme, histone acetyltransferases (HATs) and histone deacetylases (HDACs), determines the stage of histone acetylation and then the architecture of chromatin. Changes in chromatin structure result in transcriptional dysregulation of genes that are involved in cell-cycle progression, differentiation, apoptosis, and so on. Recently, HDAC inhibitors (HDACis) are identified as novel agents to keep this balance, leading to numerous researches on it for more effective strategies against cancers, including glioblastoma (GBM). This review elaborated influences on gene expression and tumorigenesis by acetylation and the antitumor mechanism of HDACis. Besdes, we outlined the preclinical and clinical advancement of HDACis in ...Continue Reading

References

Oct 10, 1975·Science·A Ruiz-CarrilloV G Allfrey
Dec 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·C D AllisI G Schulman
Apr 1, 1996·Current Opinion in Genetics & Development·J E Brownell, C D Allis
Jun 4, 1998·Current Opinion in Genetics & Development·K Luger, T J Richmond
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·S Y ArcherR A Hodin
Jan 16, 1999·Nucleic Acids Research·A P Wolffe, J J Hayes
Jan 19, 2000·Nature·B D Strahl, C D Allis
Feb 2, 2000·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·D O JonesP B Singh
Feb 17, 2000·The EMBO Journal·M A Martínez-BalbásT Kouzarides
Apr 27, 2000·Cancer Immunology, Immunotherapy : CII·J Y DouillardK Meflah
May 12, 2000·Journal of Structural Biology·A P Wolffe, D Guschin
May 16, 2000·The Journal of Biological Chemistry·K G TannerJ M Denu
Aug 3, 2000·Journal of the National Cancer Institute·P A MarksR A Rifkind
Aug 24, 2000·Proceedings of the National Academy of Sciences of the United States of America·V M RichonP A Marks
Dec 12, 2000·Biochemistry·K G TannerJ M Denu
Jan 5, 2001·Experimental Cell Research·S G Gray, T J Ekström
Mar 16, 2001·Current Opinion in Genetics & Development·M Merika, D Thanos
Jun 8, 2001·Annual Review of Biochemistry·S Y RothC D Allis
Mar 21, 2002·Nature Reviews. Cancer·P MarksW K Kelly
Apr 9, 2002·Current Biology : CB·Craig L Peterson
Jul 18, 2002·Nature Reviews. Drug Discovery·Ricky W Johnstone
Nov 7, 2002·Cell·Theodora AgaliotiDimitris Thanos
Dec 14, 2002·Biochemical and Biophysical Research Communications·You Mie LeeKyu-Won Kim
Apr 4, 2003·Current Opinion in Genetics & Development·Karolin Luger
May 9, 2003·Nature·Timothy J Richmond, Curt A Davey
Sep 3, 2003·Bioorganic & Medicinal Chemistry Letters·Carol K WadaMichael R Michaelides
Jul 1, 1961·The Biochemical Journal·E W JOHNSJ A BUTLER
May 1, 1963·The Biochemical Journal·D M PHILLIPS
Nov 1, 2003·Bioorganic & Medicinal Chemistry Letters·Anil VasudevanMichael R Michaelides

❮ Previous
Next ❯

Citations

Dec 4, 2020·International Journal of Molecular Sciences·Yuxiang Luo, Huilin Li
May 1, 2021·Cancers·Elisabete Cruz Da SilvaLaurence Choulier
Apr 20, 2021·Life Sciences·M Janaki RamaiahRajasekhar Reddy Manyam
Jun 26, 2021·Pharmacology & Therapeutics·Fengchao LangChunzhang Yang
Aug 17, 2021·Frontiers in Oncology·Rihan HaiGang Yin

❮ Previous
Next ❯

Methods Mentioned

BETA
acetylation
histone acetylation
xenograft

Clinical Trials Mentioned

NCT03838926
NCT01486277
NCT00087477
NCT00083473
NCT00005624
NCT02091063
NCT03002623
NCT01171924
NCT00238303
NCT00085540

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.